Results 191 to 199 of about 2,758 (199)
Some of the next articles are maybe not open access.

Ravulizumab: Lang wirksam bei Myasthenia gravis

NeuroTransmitter, 2023
openaire   +1 more source

Summary of opinion: Ultomiris,ravulizumab

Case Medical Research, 2019
openaire   +2 more sources

Ravulizumab auch gegen NMOSD therapeutisch wirksam

NeuroTransmitter, 2023
openaire   +1 more source

Eculizumab/Ravulizumab

Reactions Weekly
openaire   +1 more source

Ravulizumab significantly reduced relapses in AQP4+ NMOSD

Medicom Conference Report ECTRIMS 2022, 2022
openaire   +1 more source

Hocheffektive Schubprophylaxe mit Ravulizumab

InFo Neurologie + Psychiatrie
openaire   +1 more source

Ravulizumab cost effective for paroxysmal nocturnal haemoglobinuria

PharmacoEconomics & Outcomes News, 2020
openaire   +1 more source

Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension

European Journal of Neurology
Djillali Annane   +2 more
exaly  

Keine Wirksamkeit von Ravulizumab bei ALS

DNP – Die Neurologie & Psychiatrie
Albert C. Ludolph   +1 more
openaire   +1 more source
eculizumab
atypical hemolytic uremic syndrome
paroxysmal nocturnal hemoglobinuria
humans
myasthenia gravis
antibodies, monoclonal, humanized
3. good health
adult
complement inactivating agents
previous   18  19  20  

Home - About - Disclaimer - Privacy